RSS feed

Publications by Helen Heyerdahl

12 publications found

Original articles

Malenge MM, Maaland AF, Repetto-Llamazares A, Middleton B, Nijland M, Visser L, Patzke S, Heyerdahl H, Kolstad A, Stokke T, Ree AH, Dahle J (2022)
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro
PLoS One, 17 (4), e0267543
DOI 10.1371/journal.pone.0267543, PubMed 35486574

Giesen D, Hooge MNL, Nijland M, Heyerdahl H, Dahle J, de Vries EGE, Pool M (2022)
⁸⁹Zr-PET imaging to predict tumor uptake of ¹⁷⁷Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma
Sci Rep, 12 (1), 6286
DOI 10.1038/s41598-022-10139-6, PubMed 35428777

Maaland AF, Saidi A, Torgue J, Heyerdahl H, Stallons TAR, Kolstad A, Dahle J (2020)
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003
PLoS One, 15 (3), e0230526
DOI 10.1371/journal.pone.0230526, PubMed 32187209

Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, Jarlier M, Bonnefoy N, Patzke S, Stenberg V, Coopman P, Cartron G, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Bardiès M, Pouget JP (2019)
The therapeutic effectiveness of ¹⁷⁷Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
Leukemia, 34 (5), 1315-1328
DOI 10.1038/s41375-019-0677-4, PubMed 31836849

Maaland AF, Heyerdahl H, O'Shea A, Eiriksdottir B, Pascal V, Andersen JT, Kolstad A, Dahle J (2019)
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate ¹⁷⁷Lu-NNV003
Eur J Nucl Med Mol Imaging, 46 (11), 2311-2321
DOI 10.1007/s00259-019-04417-1, PubMed 31309259

Heyerdahl H, Røe K, Brevik EM, Dahle J (2013)
Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts
Int J Radiat Oncol Biol Phys, 87 (1), 153-9
DOI 10.1016/j.ijrobp.2013.04.052, PubMed 23790511

Abbas N, Heyerdahl H, Bruland ØS, Brevik EM, Dahle J (2013)
Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts
Curr Radiopharm, 6 (2), 78-86
DOI 10.2174/18744710113069990017, PubMed 23551110

Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland Ø, Dahle J (2013)
Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice
Curr Radiopharm, 6 (2), 106-16
DOI 10.2174/18744710113069990018, PubMed 23551111

Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J (2012)
Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab
PLoS One, 7 (8), e42345
DOI 10.1371/journal.pone.0042345, PubMed 22879947

Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J (2011)
Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab
EJNMMI Res, 1 (1), 18
DOI 10.1186/2191-219X-1-18, PubMed 22214432

Heyerdahl H, Krogh C, Borrebæk J, Larsen Å, Dahle J (2011)
Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab
Int J Radiat Oncol Biol Phys, 79 (2), 563-70
DOI 10.1016/j.ijrobp.2010.08.038, PubMed 21195878

Dahle J, Jonasdottir TJ, Heyerdahl H, Nesland JM, Borrebaek J, Hjelmerud AK, Larsen RH (2010)
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab
Eur J Nucl Med Mol Imaging, 37 (1), 93-102
DOI 10.1007/s00259-009-1197-7, PubMed 19593562